The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Open accessAbstract
BACKGROUND: Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. This phase 3 clinical trial compared the efficacy and safety of fidaxomicin with those of vancomycin in treating C. difficile infection. METHODS: Adults with acute symptoms of C. difficile infection and a positive result on a stool toxin test were eligible for study entry. We randomly assigned patients to receive fidaxomicin (200 mg twice daily) or vancomycin (125 mg four times daily) orally for 10 days. The primary end point was clinical cure (resolution of symptoms and no need for further therapy for C. difficile infection as of the second day after the end of the course of therapy). The secondary end points were recurrence of C. difficile infection (diarrhea and a positive result on a stool toxin test within 4 weeks after treatment) and global cure (i.e., cure with no recurrence). RESULTS: A total of 629 patients were enrolled, of whom 548 (87.1%) could be evaluated for the per-protocol analysis. The rates of clinical cure with fidaxomicin were noninferior to those with vancomycin in both the modified intention-to-treat analysis (88.2% with fidaxomicin and 85.8% with vancomycin) and the per-protocol analysis (92.1% and 89.8%, respectively). Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection, in both the modified intention-to-treat analysis (15.4% vs. 25.3%, P=0.005) and the per-protocol analysis (13.3% vs. 24.0%, P=0.004). The lower rate of recurrence was seen in patients with non–North American Pulsed Field type 1 strains. The adverse-event profile was similar for the two therapies. CONCLUSIONS: The rates of clinical cure after treatment with fidaxomicin were noninferior to those after treatment with vancomycin. Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non–North American Pulsed Field type 1 strains. (Funded by Optimer Pharmaceuticals; ClinicalTrials.gov number, NCT00314951.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Emerging Infectious Diseases · doi:10.3201/eid1406.071447 · Cited by 362
Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E., Pepin, J., Frost, E. H., Savelkoul, P., Nicholson, B., van den Berg, R. J., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01484-07 · Cited by 337
Bolton, R. P., & Culshaw, M. A. (1986) · Gut · doi:10.1136/gut.27.10.1169 · Cited by 320
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008
Kuijper, E. J., Barbut, F., Brazier, J. S., Kleinkauf, N., Eckmanns, T., Lambert, M. L., Drudy, D., Fitzpatrick, F., Wiuff, C., Brown, D. J., et al. (2008) · Eurosurveillance · doi:10.2807/ese.13.31.18942-en · Cited by 287
Al-Nassir, W. N., Sethi, A. K., Li, Y., Pultz, M. J., Riggs, M. M., & Donskey, C. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00090-08 · Cited by 242
Hecht, D. W., Galang, M. A., Sambol, S. P., Osmolski, J. R., Johnson, S., & Gerding, D. N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-06 · Cited by 228
Tannock, G. W., Munro, K., Taylor, C., Lawley, B., Young, W., Byrne, B., Emery, J., & Louie, T. (2010) · Microbiology · doi:10.1099/mic.0.042010-0 · Cited by 217
Self-citationLouie, T. J., Emery, J., Krulicki, W., Byrne, B., & Mah, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-07 · Cited by 190
Self-citationPépin, J., Valiquette, L., Gagnon, S., Routhier, S., & Brazeau, I. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01539.x · Cited by 175
Clabots, C. R., Johnson, S., Bettin, K. M., Mathie, P. A., Mulligan, M. E., Schaberg, D. R., Peterson, L. R., & Gerding, D. N. (1993) · Journal of Clinical Microbiology · doi:10.1128/jcm.31.7.1870-1875.1993 · Cited by 170
Recurrences of Clostridium difficile Diarrhea Not Caused by the Original Infecting Organism
Johnson, S., Adelmann, A., Clabots, C. R., Peterson, L. R., & Gerding, D. N. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.340 · Cited by 163
Recurrent Clostridium Difficile
Maroo, S., & Lamont, J. T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.044 · Cited by 163
Attributable Outcomes of EndemicClostridium difficile–associated Disease in Nonsurgical Patients
Dubberke, E. R., Butler, A. M., Reske, K. A., Agniel, D. M., Olsen, M. A. A., D’Angelo, G., McDonald, L. C., & Fraser, V. J. (2008) · Emerging infectious diseases · doi:10.3201/eid1407.070867 · Cited by 156
In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria
Finegold, S. M., Molitoris, D. R., Väisänen, M., Song, Y., Liu, C., & Bolaňos, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4898-4902.2004 · Cited by 122
Clostridium difficile–associated diarrhea: an emerging threat to pregnant women
Rouphael, N., O’Donnell, J. A., Bhatnagar, J., Lewis, F. M. T., Polgreen, P. M., Beekmann, S. E., Guarner, J., Killgore, G., Coffman, B., Campbell, J., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.01.062 · Cited by 119
Louie, T., Miller, M., Donskey, C. J., Mullane, K. M., & Goldstein, E. J. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01442-07 · Cited by 112
Self-citationIn Vitro Activity of OPT-80 against Clostridium difficile
Ackermann, G., Löffler, B., Adler, D., & Rodloff, A. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2280-2282.2004 · Cited by 110
Clinical Severity of Clostridium difficile PCR Ribotype 027: A Case-Case Study
Morgan, O. W., Rodrigues, B., Elston, T., Verlander, N. Q., Brown, D. F. J., Brazier, J. S., & Reacher, M. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001812 · Cited by 106
Credito, K. L., & Appelbaum, P. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4430-4434.2004 · Cited by 97
Shue, Y., Sears, P. S., Shangle, S., Walsh, R. B., Lee, C., Gorbach, S. L., Okumu, F. W., & Preston, R. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01045-07 · Cited by 93
Self-citationThe Case for Vancomycin as the Preferred Drug for Treatment ofClostridium difficileInfection
Bartlett, J. G. (2008) · Clinical Infectious Diseases · doi:10.1086/587654 · Cited by 91
Clostridium difficile Strain NAP-1 Is Not Associated With Severe Disease in a Nonepidemic Setting
Cloud, J. W., Noddin, L., Pressman, A., Hu, M. Y., & Kelly, C. P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.018 · Cited by 90
Karlowsky, J. A., Laing, N. M., & Zhanel, G. G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-08 · Cited by 62
The Second International Conference on Women and Infectious Diseases
McDonald, M., & Romero‐Steiner, S. (2006) · Emerging infectious diseases · doi:10.3201/eid1211.061025 · Cited by 12
Cited by
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Clostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Metadata
- Authors
- Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-03
- Volume
- 364
- Issue
- 5
- Pages
- 422-431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113556993
- Cited by
- 1,585
- References
- 34
- FWCI
- 96.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.